JOINT STEERING COMMITTEE

TERRY MAGNUSON, PH.D.

Terry Magnuson, PhD, is vice chancellor for research at UNC-Chapel Hill and the Sarah Graham Kenan Professor of genetics. He leads a campus-wide research program that attracts $1 billion in contract and grant funding, connects academic units across campus with university priorities, and oversees research support offices as well as 14 research centers and institutes.

Dr. Magnuson is a world-renowned geneticist who studies chromatin and gene expression in various diseases. He joined the UNC School of Medicine in 2000 to create its $245 million-backed genetics and genomics program and served as the founding chair of the genetics department in the UNC School of Medicine, and in 2010 he was named vice dean for research in the School of Medicine. He is a member of the National Institutes of Health Council of Councils, an exclusive group of the top minds in the nation charged with guiding research projects that transcend the National Institute of Health’s centers and institutes. He was appointed by the National Academies to establish guidelines for work with human embryonic stem cells and served as vice chair of the National Academy of Medicine committee evaluating the California Institute for Regenerative Medicine. He currently serves as vice president of the Genetics Society of America.

Read More Read Less

BLOSSOM DAMANIA, PH.D.

Blossom Damania, PhD, is vice dean for research at the UNC School of Medicine and the Boshamer Distinguished Professor of microbiology and immunology. She is also a member and co-director of the Virology and Global Oncology programs in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.

Dr. Damania's research focuses on oncogenic human viruses, host-pathogen interactions and virus-associated cancers. She has received several honors for her work, including being named a V Foundation for Cancer Research Scholar, an AACR Gertrude B. Elion Research Scholar, a Burroughs Welcome Investigator in the Pathogenesis of Infectious Disease, an American Heart Established Investigator, and a Leukemia & Lymphoma Society Scholar. She was named a Kavli fellow of the National Academy of Science and a fellow of the American Academy of Microbiology. She served as a member for the Report on Carcinogens Monograph by the National Toxicology Program. Dr. Damania currently serves as senior editor for several academic journals and is also the chair of the National Cancer Institute (NCI) Board of Scientific Advisors on HIV/AIDS Malignancies.

Read More Read Less

JOHN BAMFORTH, PH.D.

John Bamforth, Ph.D., is the director of the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy. The Eshelman Institute for Innovation was established in 2014 with a $100 million gift from Dr. Fred Eshelman. The Institute aims to accelerate the creation and development of ideas leading to discoveries of new medicines and technologies, and transformative changes in pharmacy/pharmaceutical sciences education and health care. Bamforth will vigorously pursue the mission and goals of the Institute, while developing new strategies to put the Institute on a path to sustained growth.

Bamforth comes to the School after almost 30 years with Eli Lilly and Company. In his most recent role at Lilly, he served as the vice president and chief marketing officer for a broad portfolio including products for cardiovascular, immunological, pain and neuro-degenerative disorders. Bamforth completed his Bachelor of Pharmacy at the University of Bath in Bath, England; and earned his Ph.D. at Aston University in Birmingham, England.

Read More Read Less

BILL SLATTERY

William Slattery is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for ten years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Read More Read Less

PETER STEELMAN

Peter Steelman is a Partner on the Pharmaceuticals group at Deerfield and joined the Firm in 2013. Mr. Steelman was a co-founder of FSC Laboratories, Inc., a pediatric-focused specialty pharmaceutical company acquired by Deerfield in 2013, where Mr. Steelman had been President and CEO from 2004 through its sale in 2016. Prior to FSC, he spent 12 years in healthcare corporate and investment banking at Wachovia Capital Markets, Bank of Montreal and Citicorp. Before receiving his M.B.A. from Columbia Business School, Mr. Steelman was an equity research associate at Kidder, Peabody & Co. covering commercial banks. Mr. Steelman received his B.A. from DePauw University.

Read More Read Less

IAN HARDY

Ian Hardy, Ph.D., is Vice President of Chemistry, Manufacturing & Controls (CMC) for Deerfield Discovery and Development, LLC, and joined Deerfield in 2019. He is responsible for leading CMC development, manufacturing and supply chain activities for all therapeutic modalities for Deerfield’s academic translator companies and some early stage portfolio companies. Dr. Hardy has over 25 years of industry experience leading CMC development activities from preclinical through commercialization and lifecycle management in both large pharma at GlaxoSmithKline, AstraZeneca and Merck, as well as emerging biopharmaceutical companies, most recently Lycera. Dr. Hardy holds a Ph.D. degree in Pharmaceutics from the University of Nottingham and an M.B.A. from Warwick Business School.

Read More Read Less

SCIENTIFIC COLLABORATION DIRECTOR

JON COLLINS, PH.D.

Jon Collins, Ph.D. recently joined Pinnacle Hill as CSO after a 24-year career at GlaxoSmithKline, with 8 years leading joint academia-GSK drug discovery collaborations across North America as Director of Discovery Partnerships with Academia. Dr. Collins has extensive experience leading multidisciplinary drug discovery research teams that span all phases of early drug discovery including therapeutic target selection and validation, compound screening, hit identification and lead optimization to clinical candidate selection in metabolic, cardiovascular, musculoskeletal, hematological, and inflammatory diseases. He has served as a co-author on 80 scientific publications in peer-reviewed scientific journals and is an inventor on 16 patents or patent applications claiming small molecule composition of matter for 6 clinical development compounds which modulate nuclear receptors, a GPCR, and a transporter. Dr. Collins has also served as a scientific advisor for the University of Michigan Therapeutic Innovation Fund, a member of the Duke-Coulter Translational Partnership Oversight Committee, and a member of the Newco Selections Committee for BioLabs NC in Durham, NC. Dr. Collins received his BS degree in chemistry from the University of North Carolina at Chapel Hill and a PhD in organic chemistry from Indiana University at Bloomington. He completed a postdoctoral fellowship at Harvard University in the lab of Professor Stuart Schreiber.

Read More Read Less

TERRY MAGNUSON, PH.D.

Read More
Read Less

BLOSSOM DAMANIA, PH.D.

Read More
Read Less

Terry Magnuson, PhD, is vice chancellor for research at UNC-Chapel Hill and the Sarah Graham Kenan Professor of genetics. He leads a campus-wide research program that attracts $1 billion in contract and grant funding, connects academic units across campus with university priorities, and oversees research support offices as well as 14 research centers and institutes.

Dr. Magnuson is a world-renowned geneticist who studies chromatin and gene expression in various diseases. He joined the UNC School of Medicine in 2000 to create its $245 million-backed genetics and genomics program and served as the founding chair of the genetics department in the UNC School of Medicine, and in 2010 he was named vice dean for research in the School of Medicine. He is a member of the National Institutes of Health Council of Councils, an exclusive group of the top minds in the nation charged with guiding research projects that transcend the National Institute of Health’s centers and institutes. He was appointed by the National Academies to establish guidelines for work with human embryonic stem cells and served as vice chair of the National Academy of Medicine committee evaluating the California Institute for Regenerative Medicine. He currently serves as vice president of the Genetics Society of America.

Blossom Damania, PhD, is vice dean for research at the UNC School of Medicine and the Boshamer Distinguished Professor of microbiology and immunology. She is also a member and co-director of the Virology and Global Oncology programs in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.

Dr. Damania's research focuses on oncogenic human viruses, host-pathogen interactions and virus-associated cancers. She has received several honors for her work, including being named a V Foundation for Cancer Research Scholar, an AACR Gertrude B. Elion Research Scholar, a Burroughs Welcome Investigator in the Pathogenesis of Infectious Disease, an American Heart Established Investigator, and a Leukemia & Lymphoma Society Scholar. She was named a Kavli fellow of the National Academy of Science and a fellow of the American Academy of Microbiology. She served as a member for the Report on Carcinogens Monograph by the National Toxicology Program. Dr. Damania currently serves as senior editor for several academic journals and is also the chair of the National Cancer Institute (NCI) Board of Scientific Advisors on HIV/AIDS Malignancies.


JOHN BAMFORTH, PH.D.

Read More
Read Less

BILL SLATTERY

Read More
Read Less

John Bamforth, Ph.D., is the director of the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy. The Eshelman Institute for Innovation was established in 2014 with a $100 million gift from Dr. Fred Eshelman. The Institute aims to accelerate the creation and development of ideas leading to discoveries of new medicines and technologies, and transformative changes in pharmacy/pharmaceutical sciences education and health care. Bamforth will vigorously pursue the mission and goals of the Institute, while developing new strategies to put the Institute on a path to sustained growth.

Bamforth comes to the School after almost 30 years with Eli Lilly and Company. In his most recent role at Lilly, he served as the vice president and chief marketing officer for a broad portfolio including products for cardiovascular, immunological, pain and neuro-degenerative disorders. Bamforth completed his Bachelor of Pharmacy at the University of Bath in Bath, England; and earned his Ph.D. at Aston University in Birmingham, England.

William Slattery is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for ten years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.


PETER STEELMAN

Read More
Read Less

IAN HARDY

Read More
Read Less

Peter Steelman is a Partner on the Pharmaceuticals group at Deerfield and joined the Firm in 2013. Mr. Steelman was a co-founder of FSC Laboratories, Inc., a pediatric-focused specialty pharmaceutical company acquired by Deerfield in 2013, where Mr. Steelman had been President and CEO from 2004 through its sale in 2016. Prior to FSC, he spent 12 years in healthcare corporate and investment banking at Wachovia Capital Markets, Bank of Montreal and Citicorp. Before receiving his M.B.A. from Columbia Business School, Mr. Steelman was an equity research associate at Kidder, Peabody & Co. covering commercial banks. Mr. Steelman received his B.A. from DePauw University.

Ian Hardy, Ph.D., is Vice President of Chemistry, Manufacturing & Controls (CMC) for Deerfield Discovery and Development, LLC, and joined Deerfield in 2019. He is responsible for leading CMC development, manufacturing and supply chain activities for all therapeutic modalities for Deerfield’s academic translator companies and some early stage portfolio companies. Dr. Hardy has over 25 years of industry experience leading CMC development activities from preclinical through commercialization and lifecycle management in both large pharma at GlaxoSmithKline, AstraZeneca and Merck, as well as emerging biopharmaceutical companies, most recently Lycera. Dr. Hardy holds a Ph.D. degree in Pharmaceutics from the University of Nottingham and an M.B.A. from Warwick Business School.

SCIENTIFIC COLLABORATION DIRECTOR


JON COLLINS, PH.D.

Read More
Read Less

Jon Collins, Ph.D. recently joined Pinnacle Hill as CSO after a 24-year career at GlaxoSmithKline, with 8 years leading joint academia-GSK drug discovery collaborations across North America as Director of Discovery Partnerships with Academia. Dr. Collins has extensive experience leading multidisciplinary drug discovery research teams that span all phases of early drug discovery including therapeutic target selection and validation, compound screening, hit identification and lead optimization to clinical candidate selection in metabolic, cardiovascular, musculoskeletal, hematological, and inflammatory diseases. He has served as a co-author on 80 scientific publications in peer-reviewed scientific journals and is an inventor on 16 patents or patent applications claiming small molecule composition of matter for 6 clinical development compounds which modulate nuclear receptors, a GPCR, and a transporter. Dr. Collins has also served as a scientific advisor for the University of Michigan Therapeutic Innovation Fund, a member of the Duke-Coulter Translational Partnership Oversight Committee, and a member of the Newco Selections Committee for BioLabs NC in Durham, NC. Dr. Collins received his BS degree in chemistry from the University of North Carolina at Chapel Hill and a PhD in organic chemistry from Indiana University at Bloomington. He completed a postdoctoral fellowship at Harvard University in the lab of Professor Stuart Schreiber.